Prof. Dr. Andreas Mackensen

Lehrstuhl für Innere Medizin V

Prevention of CMV/EBV reactivation by double-specific T cells in patients after allogeneic stem cell transplantation: results from the randomized phase I/IIa MULTIVIR-01 study (2023) Gerbitz A, Gary R, Aigner M, Moosmann A, Kremer A, Schmid C, Hirschbuehl K, et al. Journal article CAR T-cell therapy in autoimmune diseases (2023) Schett G, Mackensen A, Mougiakakos D Journal article, Review article Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells. (2023) Bergmann C, Müller F, Distler J, Györfi AH, Völkl S, Aigner M, Kretschmann S, et al. Journal article, Letter Case Report: IBD-like colitis following CAR T cell therapy for diffuse large B cell lymphoma (2023) Zundler S, Vitali F, Kharboutli S, Völkl S, Polifka I, Mackensen A, Atreya R, et al. Journal article The metabolic profile of reconstituting T-cells, NK-cells, and monocytes following autologous stem cell transplantation and its impact on outcome (2022) Richter S, Böttcher M, Mackensen A, Ullrich E, Jacobs B, Mougiakakos D, Völkl S Journal article Blocking the CD47-Sirpa Axis Enhances Tafasitamab-Mediated Phagocytosis (2022) Biedermann A, Mangelberger-Eberl D, Mougiakakos D, Büttner-Herold M, Flamann C, Kellner C, Altmeyer S, et al. Conference contribution Sars-Cov-2 Vaccine-Induced Cellular and Humoral Immunity in Patients after CD19.CAR-T Cell Therapy (2022) Reimann H, Kremer A, Blumenberg V, Schmidt K, Aigner M, Kremer A, Tenbusch M, et al. Conference contribution Detection of Signature Double-Negative T Cells Is a Reliable Marker for ALPS Associated with FAS Mutation (2022) Eisenhauer N, Miano M, Naumann-Bartsch N, Leyh J, Terranova P, Hinze C, Aigner M, et al. Conference contribution Early Real Time Quantification of CD19. CAR T Cells By Flow Cytometry As a Predictive Biomarker for Response in Patients with R/R LBCL (2022) Blumenberg V, Busch G, Baumann S, Jitschin R, Winkelmann M, Hellwig K, Rejeski K, et al. Conference contribution Inferior Outcomes of EU Vs. US Patients with Relapsed/Refractory Large B-Cell Lymphoma after CD19 CAR T-Cell Therapy Are Associated with Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization and CAR-T Product Selection (2022) Buecklein VL, Perez-Perez A, Rejeski K, Iacoboni G, Jurinovic V, Holtick U, Penack O, et al. Conference contribution